Previous 10 | Next 10 |
Calliditas Announces Submission of Marketing Authorisation Application for Nefecon to the European Medicines Agency PR Newswire STOCKHOLM , May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today...
Calliditas Therapeutics to Present at Jefferies Virtual Healthcare Conference PR Newswire STOCKHOLM , May 28, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that management will present at the Jefferies Virtual Healthcare ...
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM , May 27, 2021 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on ...
Calliditas Therapeutics AB (CALT) Q1 2021 Earnings Conference Call May 18, 2021 08:30 AM ET Company Participants Renée Lucander - CEO Richard Philipson - Chief Medical Officer Fredrik Johansson - CFO Andrew Udell - President, North America Conference Call Participants Yigal Nochomovitz -...
The following slide deck was published by Calliditas Therapeutics AB (publ) in conjunction with their 2021 Q1 earnings call. For further details see: Calliditas Therapeutics AB (publ) 2021 Q1 - Results - Earnings Call Presentation
Calliditas Therapeutics (CALT): Q1 GAAP EPS of -SEK 2.51.Cash amounted to SEK 867.3MPress Release For further details see: Calliditas Therapeutics reports Q1 results
Interim Report Q1, 2021 PR Newswire STOCKHOLM , May 18, 2021 /PRNewswire/ -- Filing of New Drug Application submission to the FDA "Following the positive top line readout of our pivotal Phase 3 trial NefIgArd, which met both the primary and key secondary ...
Calliditas Therapeutics to host conference call to provide Business Update for the first quarter of 2021 PR Newswire STOCKHOLM , May 14, 2021 /PRNewswire/ -- On May 18 th , 2021, Calliditas Therapeutics AB (publ) ("Calliditas") will publish its financia...
Calliditas promotes Andrew Udell to President, North America PR Newswire STOCKHOLM , May 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that former Head of North America Commerc...
ADMA Biologics (ADMA) +25% after receiving FDA approval for increased IVIG production scale.Akari Therapeutics (AKTX) +12% on receiving FDA fast track designation for Nomacopan.Sphere 3D Corp. (ANY) +12%.RiceBran Technologies (RIBT) +11%.Boxlight Corporation (BOXL) +11%.Calliditas T...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...